FRY: A Drug Target / Disease Biomarker (G10129)

Target Name: FRY

NCBI ID: G10129

Content of Review Report on FRY Target / Biomarker

FRY

Other Name(s): Protein furry homolog | C13orf14 | 13CDNA73 | furry homolog | BA37E23.1 | FRY_HUMAN | CG003 | bA207N4.2 | WUGSC:H_2G3A.1 | bA37E23.1 | 214K23.2 | BA207N4.2 | FRY microtubule binding protein

FRY: A Drug Target / Disease Biomarker

Frry is a protein that is expressed in the brain and is known to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is made by the neurotransmitter GABA, which is a well-known stress-reducing molecule that is involved in many important cellular processes in the brain.

Recent studies have suggested that Frry may be a drug target or biomarker for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other forms of dementia. This is because Frry is involved in the production and function of many of the proteins that are involved in the development and progression of these diseases.

One of the key ways in which Frry may be involved in the development and progression of neurodegenerative diseases is by contributing to the production of abnormal proteins that are involved in the disease. For example, studies have shown that people with Alzheimer's disease have increased levels of Frry in their brains, and that these levels are associated with the severity of the disease.

Additionally, Frry has also been shown to be involved in the regulation of normal cellular processes that are important for the health and function of the brain. For example, studies have shown that Frry is involved in the production and degradation of the protein tau, which is involved in the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease.

Another potential mechanism by which Frry may be involved in the development and progression of neurodegenerative diseases is by contributing to the immune response against the disease. Studies have shown that people with Alzheimer's disease have an overactive immune system, which may contribute to the development and progression of the disease.

Frry is also of interest as a potential biomarker for neurodegenerative diseases because it is expressed in the brain and can be targeted directly with drugs. This is Unlike many other proteins that are involved in the development and progression of neurodegenerative diseases, which are difficult to target with small molecules.

In conclusion, Frry is a protein that is expressed in the brain and is involved in the development and progression of neurodegenerative diseases. Its role in these processes may be as a drug target or biomarker, and its potential as a therapeutic target is being investigated in ongoing clinical trials. Further research is needed to fully understand the role of Frry in the development and progression of neurodegenerative diseases.

Protein Name: FRY Microtubule Binding Protein

Functions: Plays a crucial role in the structural integrity of mitotic centrosomes and in the maintenance of spindle bipolarity by promoting PLK1 activity at the spindle poles in early mitosis. May function as a scaffold promoting the interaction between AURKA and PLK1, thereby enhancing AURKA-mediated PLK1 phosphorylation

The "FRY Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRY comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets